Table 3 Baseline clinical characteristics for the studied population after matching
Characteristics | Short-time group (n = 432) | Long-time group (n = 432) | P value |
|---|---|---|---|
Age (years) | 68 ± 11 | 67 ± 13 | 0.22 |
Male sex (n,%) | 280 (64.7%) | 276 (63.9%) | 0.89 |
Diabetes mellitus (n,%) | 172 (39.7%) | 174 (40.3%) | 0.94 |
Hypertension (n,%) | 270 (62.4%) | 272 (63.0%) | 0.95 |
Current smoker (n,%) | 137 (31.8%) | 135 (31.3%) | 0.94 |
Hypercholesterolemia (n,%) | 270 (62.4%) | 276 (63.8%) | 0.94 |
Previous MI (n, %) | 30 (6.9%) | 28 (6.5%) | 0.89 |
Previous PCI (n, %) | 52 (12.1%) | 55 (12.7%) | 0.84 |
Prior coronary bypass surgery (n, %) | 5 (1.2%) | 4 (0.9%) | 1.00 |
Renal insufficiency (n, %) | 27 (6.3%) | 30 (6.9%) | 0.78 |
Left ventricular ejection fraction (%) | 43 ± 11 | 42 ± 8 | 0.13 |
EF < 40% (n, %) | 38 (21.9%) | 38 (21.9%) | 1.00 |
Peak troponin I (ng/ml) | 16.45 ± 1.52 | 16.28 ± 1.82 | 0.14 |
hs-CRP (mg/L) | 22.8 ± 3.3 | 22.9 ± 3.1 | 0.64 |
BNP (pg/mL) | 232 ± 24 | 235 ± 23 | 0.06 |
Radial Access (n, %) | 387 (89.5%) | 376 (87.0%) | 0.29 |
Targeted vessel (n, %) | |||
LM | 8 (1.9%) | 9 (2.1%) | 0.99 |
LAD | 145 (33.6%) | 143 (33.1%) | |
LCX | 108 (25.0%) | 110 (25.0%) | |
RCA | 170 (39.3%) | 169 (39.1%) | |
Saphenous vein graft | 1 (0.2%) | 1 (0.2%) | |
Lesion type (n, %) | |||
A | 81 (18.7%) | 83 (19.3%) | 0.99 |
B1 | 52 (12.1%) | 55 (12.7%) | |
B2 | 167 (38.7%) | 164 (37.9%) | |
C | 132 (30.5%) | 130 (30.1%) | |
Multivessel disease (n, %) | 91 (21.1%) | 93 (21.5%) | 0.93 |
Multivessel intervention (n, %) | 83 (19.2%) | 78 (18.1%) | 0.73 |
Multilesion intervention (n, %) | 124 (28.7%) | 122 (28.2%) | 0.94 |
Stent length (mm) | 24.1 ± 7.3 | 24.2 ± 8.1 | 0.85 |
Stents ≥2(n, %) | 188 (43.5%) | 173 (40.0%) | 0.33 |
Side-branch involvement (n, %) | 99 (23.0%) | 93 (21.5%) | 0.94 |
Calcification lesion (n, %) | 121 (28%) | 118 (27.3%) | 0.88 |
Total occlusion lesion (n, %) | 96 (22.2%) | 98 (22.7%) | 0.94 |
Usage of ticagrelor (n, %) | 186 (43.1%) | 178 (41.2%) | 0.78 |
Usage of glycoprotein IIb/IIIa inhibitors (n, %) | 135 (31.1%) | 138 (31.9%) | 0.88 |